

Applicants : David J. Pinsky et al.
U.S. Serial No.: NOT YET KNOWN
Filed : HERewith
Page 2

human subject.

2. (Amended) The method of claim 1, wherein the active polypeptide fragment of CD39 polypeptide is administered and is a mutated or a truncated form of the CD39 polypeptide.
9. (Amended) The method of claim 1, wherein the administration of the CD39 polypeptide or the active polypeptide fragment thereof is effected at the onset of stroke in the human subject.
10. Amended) The method of claim 1, wherein the administration of the CD39 polypeptide or the active polypeptide fragment thereof is effected prior to stroke onset in the human subject.
11. (Amended) The method of claim 1, wherein the administration of the CD39 polypeptide or the active polypeptide fragment thereof is effected after stroke onset in the human subject.
17. (Amended) A method for determining whether a compound inhibits platelet aggregation or leukocyte accumulation by increasing ADP catabolism and does not increase incidence of intracerebral hemorrhage, so as to treat or prevent thrombotic or ischemic disorder in a subject, comprising:

Applicants : David J. Pinsky et al.
U.S. Serial No.: NOT YET KNOWN
Filed : HEREWITH
Page 3

- (a) administering the compound to an animal, which is a model for the thrombotic or ischemic disorder, before, concurrently with or after step (b);
- (b) inducing the thrombotic or ischemic disorder in the animal;
- (c) measuring the thrombotic or ischemic disorder outcome and the incidence of intracerebral hemorrhage in the animal;
- (d) measuring platelet deposition and/or fibrin deposition and/or accumulation of leukocytes in ischemic tissue in the animal; and
- (e) comparing the thrombotic or ischemic disorder outcome and the platelet and/or fibrin deposition and/or accumulation of leukocytes in the presence of the compound with in the absence of the compound so as to determine whether the compound is capable of treating or preventing the thrombotic or ischemic disorder in the subject without increasing the incidence of intracerebral hemorrhage.--

REMARKS


By this Preliminary Amendment applicant has hereinabove amended

Applicants : David J. Pinsky et al.
U.S. Serial No.: NOT YET KNOWN
Filed : HEREWITH
Page 4

claims 1, 2, 9, 10, 11 and 17. A mark-up copy of the amendments is attached hereto as Exhibit 1. Support for amended claim 1 can be found in the specification as originally filed at, inter alia, page 6, lines 2-8, page 18, lines 20-25. Support for amended claim 2 can be found in the specification as originally filed at, inter alia, page 6, lines 10-12. Support for amended claim 9 can be found in the specification as originally filed at, inter alia, page 15, lines 18 to 19. Support for amended claim 10 can be found in the specification as originally filed at, inter alia, page 16, lines 21-23. Support for amended claim 11 can be found in the specification as originally filed at, inter alia, page 16, lines 21 to 27. These amendments raise no issue of new matter. Accordingly applicant respectfully requests that these amendments be entered.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invite the Examiner to telephone him at the number provided below.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400